Drug Trial Radar · NCT05623267
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
Last checked: Nov 20, 2026Latest source record: Aug 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
346
Planned (sponsor's estimate)
Start
Jul 1, 2023
Primary completion
Dec 31, 2025
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the efficacy of sugemalimab consolidation therapy versus placebo in patients with LS-SCLC who had not progressed following Concurrent or Sequential Chemoradiotherapy.
Conditions
- Limited Stage Small Cell Lung Cancer
Interventions
SugemalimabDrug
Recombinant anti-PD-L1 fully human monoclonal antibody
PlaceboDrug
Placebo of Sugemalimab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progress Free Survival(PFS)Time frame: up to 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.